Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed

Journal of Clinical Oncology

Volumn 20, Issue 1, 2002, Pages 205-213

  Keating, M J ^a   Cazin, B ^a   Coutre S ^a   Birhiray, R ^a   Kovacsovics, T ^a   Langer, W ^a   Leber, B ^a   Maughan, T ^a   Rai, K ^a   Tjonnfjord G ^a   Bekradda, M ^a   Itzhaki, M ^a   Herait P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CD2 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; CD7 ANTIGEN; CD8 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LIVER; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SPLEEN; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; CONSUMER PRODUCT SAFETY; FEMALE; HEMATOLOGIC DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA, T-CELL; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; TIME FACTORS;

EID: 0036139106     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.1.205     Document Type: Article

References (25)

1. T-small lymphocyte disorders
2. Surface bound immunoglobulins as a cell marker in human lymphoproliferative diseases
3. Prolymphocytic leukaemia
4. Similarities between T-cell chronic lymphocytic leukemia and the small-cell variant of T-prolymphocytic leukemia
5. Is there a T-cell form of chronic lymphocytic leukemia?
6. Pentostatin in prolymphocytic leukemia: Phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group
7. The role of pentostatin in the treatment of T-cell malignancies: Analysis of response rate in 145 patients according to disease subtype
8. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia
9. 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders
10. Treatment of refractory T-cell chronic lymphocytic leukemia with purine nucleoside analogues
11. Complete remission in T-cell prolymphocytic leukemia with 2-chlorodeoxyadenosine
12. Chlorambucil and prednisolone therapy in a patient with T-cell chronic lymphocytic leukaemia
13. Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia
14. Splenectomy in lymphoproliferative disorders: A report on 70 cases and review of the literature
15. Treatment of T prolymphocytic leukemia with allogeneic bone marrow transplantation
16. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H
17. Effects-of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype
18. Humanised monoclonal antibody therapy for rheumatoid arthritis
19. CAMPATH-1H therapy for patients with refractory CLL
20. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia: European Study Group of CAMPATH-1H treatment in chronic lymphocytic leukemia
21. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia
22. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody
23. Campath-1H in the treatment of T-prolymphocytic leukemia (T-PLL)
24. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment
25. Levels of expression of CD52 in normal and leukemic B and T cells: Correlation with in vivo therapeutic responses to Campath-1H